A Phase I study at Ohio State reported early results for an engineered CAR-T platform designed for faster manufacturing—produced in about six days, infused fresh, and targeting three B-cell proteins with OX40 co-stimulation. The trial focused on relapsed B-cell blood cancers and reported remissions with minimal side effects in early data. The approach centers on shortening ex vivo production timelines without sacrificing potency signals, aiming to reduce the time-to-treatment gap that can strand patients as disease progresses while product is manufactured.